2363

GSK appoints Emma Walmsley as CEO

pharmafile | September 20, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, GlaxoSmithKline, appointment 

GlaxoSmithKline, the UK’s biggest drugs company, has appointed Emma Walmsley as its new CEO. Walmsley will step into the vacancy left by current CEO Sir Andrew Witty who will step down in March 2017.

Walmsley joined the company in 2010 and oversees its consumer healthcare division. She had previously served at L’Oreal for 17 years, working in the UK, Europe, China and the US. She now becomes the most powerful woman in the FTSE100 and one of just six female chief executives.  

Hampton said: “Emma is an outstanding leader with highly valuable experience of building and running major global businesses and a strong track record of delivering growth and driving performance in healthcare.”

Walmsley said: “I am delighted and honoured to be appointed GSK’s next CEO. I’m looking forward to working with Andrew and other leaders over the next few months to ensure a smooth handover and to develop plans for 2017 and beyond.”

Matt Fellows

Related Content

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental …

GSK shares results from phase 3 trial for gonorrhoea treatment

GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …

GSK’s meningococcal vaccine candidate accepted for FDA review

GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …

Latest content